Previous 10 | Next 10 |
Philadelphia, Pennsylvania--(Newsfile Corp. - January 4, 2024) - Berger Montague announces that a class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired SCYNEXIS, Inc. ("Scynexis") (NASDAQ: SCYX) securities. If you suffered lo...
2024-01-03 09:00:11 ET Scynexis ( NASDAQ: SCYX ) fell ~9% premarket Wednesday after disclosing that British drugmaker GSK ( GSK ) amended its license agreement for its antifungal drug Brexafemme (ibrexafungerp tablets). The amendment relates to the recent product recall ...
2024-01-03 08:34:29 ET More on Pre-market losers & stocks. Canaan Inc. (CAN) Q3 2023 Earnings Call Transcript Flex: Margin Expansion Is The Name Of The Game Flex Ltd. (FLEX) Q2 2024 Earnings Call Transcript Flex completes spin-off of remaining interest in...
2024-01-02 16:55:53 ET Gainers: Bloomin' Brands ( BLMN ) +6% . Arcutis Biotherapeutics ( ARQT ) +6% . Stronghold Digital Mining ( SDIG ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Guardant Health ( GH ) +3% . Losers: ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and ...
NEW YORK, NY / ACCESSWIRE / December 20, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SCYNEXIS, Inc. ("Scynexis" or "the Company") (NASDAQ:SCYX). Investors who purchased Scynexis securities prior to March 31, 2023, and continue to hol...
2023-12-18 18:46:23 ET Summary Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sales of over $500M. Ibrexafungerp commercialization ...
Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and Sept...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Scynexis between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights,...
News, Short Squeeze, Breakout and More Instantly...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity ...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY C...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to o...